Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
about
Fluoxetine for adult overweight or obese peopleAntidepressants for polycystic ovary syndromeAntidepressants for polycystic ovary syndromePolymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetesTwo functional serotonin polymorphisms moderate the effect of food reinforcement on BMI.Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats.The potential use of selective 5-HT2C agonists in treating obesity.The association between sleep patterns and overweight/obesity in Chinese children: a cross-sectional study.Subtle alterations in breathing and heart rate control in the 5-HT1A receptor knockout mouse in early postnatal developmentPotential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.Daily male exposure attenuates estrous cycle disruption by fluoxetineClinical pharmacology of the serotonin receptor agonist, zolmitriptan.Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat massSystemic treatment with D-fenfluramine, but not sibutramine, blocks cue-induced reinstatement of food-seeking behavior in the rat.Changes in feeding and locomotion induced by amphetamine analogs in rats.Serotonin contracts the rat mesenteric artery by inhibiting 4-aminopyridine-sensitive Kv channels via the 5-HT2A receptor and Src tyrosine kinase.Hypothalamic regulation of food intake and clinical therapeutic applications.Genetic polymorphism of serotonin transporter 5-HTTLPR: involvement in smoking behaviour.Appetite control and obesity.Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.The therapeutic potential of GPR43: a novel role in modulating metabolic health.Ecological effects of pharmaceuticals in aquatic systems--impacts through behavioural alterations.What do we know about the nutritional status of the very old? Insights from three cohorts of advanced age from the UK and New Zealand.An extended reinforcement learning model of basal ganglia to understand the contributions of serotonin and dopamine in risk-based decision making, reward prediction, and punishment learning.A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat.Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward.Effects of an acute alpha-lactalbumin manipulation on mood and food hedonics in high- and low-trait anxiety individuals.5-HT inhibition of rat insulin 2 promoter Cre recombinase transgene and proopiomelanocortin neuron excitability in the mouse arcuate nucleus.Obesity, diabetes, and associated risk factors.Comparative effects of intraduodenal amino acid infusions on food intake and gut hormone release in healthy males.NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.Changes in plasma amino Acid levels do not predict satiety and weight loss on diets with modified macronutrient composition.An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.The capsaicin analog nonivamide decreases total energy intake from a standardized breakfast and enhances plasma serotonin levels in moderately overweight men after administered in an oral glucose tolerance test: a randomized, crossover trial.Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.Anxiolytic effect of serotonin depletion in the novelty-induced hypophagia test.Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight.
P2860
Q24188314-FFFD8E63-B737-4A98-A384-C866F3D918F6Q24202704-D7E5BBAF-A69E-4E62-BCAE-2C427E0A36B6Q24234515-DF55D363-5AE2-469E-851A-6360FE52057EQ28475961-0F7B3D99-254E-481E-B856-BA5142A8488FQ33726497-4D633BBD-A13B-4C57-8437-7AAA8E30D6F0Q33843546-A26E85F0-ACE2-4BFC-A2BD-082C84B287BEQ34497896-52D20105-A859-4A76-B830-38E0F7613703Q36015833-D67A1413-6116-4284-846C-E7A0399804C4Q36473645-1F2FAF37-AC2C-4D30-A26C-C62B4226B470Q36576592-1B79053F-0D38-4325-9174-04B1F9C555DEQ36628764-CA0E1348-50E2-4F02-9D6E-D79D20D2DB8EQ37008907-3EF4EA3E-26DD-4C16-9216-453A3C3D2D4FQ37040652-04DE845C-CDAF-4046-80BA-5D8F60048966Q37366803-AF4CB6AB-528F-4D59-A3D3-D216DBAB3F80Q37379197-0E666CD5-4A6B-40B5-9419-0DF81AF2C0AEQ37432060-28991C68-5706-4332-B6F7-F8A7AEB748D8Q37494269-7A00EB31-6129-4146-B9B3-EA6C6B93E4D7Q37890196-5BB3D89D-E7B3-45FF-B92C-A6AA9AE3DCD2Q38022686-DD6BA1A4-D7D9-492F-BE72-3FA62591AE00Q38088731-EC992DAC-A7F0-418E-9C7A-F80151F6301DQ38121495-D5B59E02-3D42-4E5A-921B-5B688E69B0E1Q38269160-C91950B7-A804-46D8-BCEE-78D0DD9BE15BQ38831394-EF4C04DB-D713-4597-9D43-5BD0F874CE44Q38921547-222DED34-DC33-42DC-B50E-2DF00FD141DFQ39816708-02890781-8BEA-47E0-903A-E44531E5228DQ40482498-2CEBF8CE-A3FE-4858-B939-1596906D9DDEQ42171474-80ACB4D7-FB65-4483-B094-ADE848E50380Q43122112-612BC208-1166-46B0-B8B9-C519AF3FC692Q43155942-1C9C1B5B-05B5-44B7-BCD1-C204616B152BQ46885883-E829D632-9399-43B1-B213-F3406DE172DCQ47111410-11575D68-4614-4327-92E6-1868F2E55AAEQ47273564-AE31B011-F106-46C5-9205-2EF6D9803D50Q47285487-211C5485-FA49-494F-A8E4-B6767B378519Q47321829-AF767DC2-98BB-4648-88FE-3810506F6963Q47588598-3C42916E-9C96-41B5-97FC-13829DE9C133Q47738255-A2229D96-6433-42F4-87BD-A17F19B19E9CQ47776914-65227938-0EEE-40AC-9984-3A41C2C99A1DQ48013285-2F8498EC-7A6B-491C-A4C6-5427706AA623Q48339675-AA63F084-CBD2-4E02-917F-D899F81D8BC8Q51321838-297C933C-AD5D-4C09-9D9A-B89669EC9937
P2860
Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@ast
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@en
type
label
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@ast
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@en
prefLabel
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@ast
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@en
P356
P1433
P1476
Serotonin (5-HT) drugs: effect ...... for the treatment of obesity.
@en
P2093
Jason C G Halford
Joanne A Harrold
P304
P356
10.2174/1389450053174550
P577
2005-03-01T00:00:00Z